Actively Recruiting
Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2025-03-28
29
Participants Needed
2
Research Sites
185 weeks
Total Duration
On this page
Sponsors
L
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
A
Academic Medical Organization of Southwestern Ontario
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) in patients planned to receive radical dose radiation. This study will use Stereotactic Ablative Radiotherapy (SABR) for treatment methods. SABR is a newer radiation treatment that delivers high-dose, precise radiation to small tumors and can be delivered more accurately than with older radiation treatment methods. It is considered a standard treatment for small lung cancers, and select cancers that have spread to the brain. The purpose of this study is to compare if the lymph node sampling procedure is valuable for determining the extend of nodal disease in metastatic Non-Small Cell Lung Cancer (NSCLC) compared to imaging alone.
CONDITIONS
Official Title
Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases
- Radical treatment intent to all sites recommended by tumor board or oncologist/surgeon
- Age 18 years or older
- Good performance status (ECOG 0-1) with life expectancy of at least 6 months
- Staging investigations completed less than 3 months before registration, including PET/CT and brain MRI or CT with contrast if MRI contraindicated, or CT chest/abdomen, bone scan, and brain MRI or CT with contrast if MRI contraindicated
- Pathologic confirmation of NSCLC
You will not qualify if you...
- Contraindication to Endobronchial Ultrasound (EBUS) or Endoscopic Ultrasound (EUS)
- Unable to provide consent for EBUS/EUS
- Contraindication to chest radiotherapy
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
London Health Sciences Centre - London Regional Cancer Program
London, Ontario, Canada, N6A 5W9
Actively Recruiting
2
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
I
Inderdeep Dhaliwal, MD
CONTACT
D
David Palma, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here